In conclusion, it is imperative to accelerate the movement of transformative agents to frontline settings, particularly those with game-changing potential such as the BCR::ABL1-directed TKIs and menin inhibitors reviewed in this review, to improve cure rates and reduce short- and long-term toxicities for children with ALL. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.